This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. BioCardia's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2024 was $0.035. BioCardia's 10-Year median PS Ratio is 36.2857. Therefore, the Median PS Value for today is $1.27.
As of today (2025-03-30), BioCardia's share price is $2.80. BioCardia's Median PS Value is $1.27. Therefore, BioCardia's Price to Median PS Value for today is 2.20.
The historical rank and industry rank for BioCardia's Median PS Value or its related term are showing as below:
BCDA'
s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.47 Med: 0.59 Max: 2.21
Current: 2.2
During the past 13 years, the highest Price to Median PS Value of BioCardia was 2.21. The lowest was 0.47. And the median was 0.59.
BCDA's Price-to-Median-PS-Value is ranked worse than 89.07% of 247
companies
in the Biotechnology industry
Industry Median: 0.7
vs BCDA: 2.20
BioCardia Median PS Value Historical Data
The historical data trend for BioCardia's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of BioCardia's Median PS Value
For the Biotechnology subindustry, BioCardia's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioCardia's Price-to-Median-PS-Value Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioCardia's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where BioCardia's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is 36.2857.
BioCardia's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.035.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioCardia (NAS:BCDA) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
BioCardia's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
2.80
/
1.27
=
2.20
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioCardia Median PS Value Related Terms
Thank you for viewing the detailed overview of BioCardia's Median PS Value provided by GuruFocus.com. Please click on the following links to see related term pages.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an "off the shelf" cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
BCDA has been successfully added to your 